Comment on Rosenstock et al. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care 2020;43:2509-2518.,Diabetes Care

当前位置： X-MOL 学术 › Diabetes Care › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Comment on Rosenstock et al. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care 2020;43:2509-2518.
Diabetes Care ( IF 16.2 ) Pub Date : 2021-11-01 , DOI: 10.2337/dc20-2987
Chinmay S Marathe _{1,

2,

3} , Karen L Jones _{2,

3,

4} , Christopher K Rayner _{2,

3,

5} , Tongzhi Wu _{2,

3,

4} , Michael Horowitz _{2,

3,

4}

Affiliation